Lamivudine/raltegravir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lamivudine/raltegravir
Combination of
LamivudineReverse-transcriptase inhibitor
RaltegravirIntegrase inhibitor
Clinical data
Trade namesDutrebis
Routes of
administration
Oral
Legal status
Legal status
Identifiers
KEGG

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a combination medication of lamivudine and raltegravir which is used in the treatment of HIV/AIDS.[1] It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1]

References[edit]

  1. ^ a b c d "Dutrebis (lamivudine and raltegravir)" (PDF). FDA. Retrieved 10 December 2017.